Please confirm that an ethics committee approval has been applied for or granted: Yes: I’m uploading the Ethics Committee Approval as a PDF file with this abstract submission

Application for ESRA Abstract Prizes: I apply as an Anesthesiologist (Aged 35 years old or less)

Background and Aims Ropivacaïne or 1-propyl-2’, 6’-pipecoloxylidide, is a non-racemic chiral amino-amide similar to Bupivacaïne in terms of structure. It differs from it by the substitution on its amine group of another group butyl replaced by a propyl group. It is considered as a pure S-levorotatory enantiomer of the molecule. Unlike Bupivacaïne, which is a racemic equimolecular mixture of the two enantiomers. The objective of our study is to integrate and to generalize the use of Ropivacaïne in spinal anesthesia.

Methods Descriptive prospective interventional comparative clinical study, for 120 adult patients were recruited and randomly divided into two groups (Ropivacaïne group and Bupivacaïne Group), 60 patients in each arm who were admitted to the operating room to undergo scheduled or urgent surgery requiring. The data collected are mainly the demographic and anthropometric characteristics. and perioperative hemodynamic parameters, namely: blood pressure (BP), heart rate (HR), incidence of acute toxicities cardiovascular. The data collected was analyzed by SPSS ‘20’ software and Excel 2013 software.

Results 120 patients were included in our study, hemodynamic stability with the use of Ropivacaïne, with low cardiovascular toxicity compared to the Bupivacaïne group satisfaction in the Ropivacaïne group.

Conclusions The anesthetic drug type Ropivacaïne is promising for spinal anesthesia. The results found in our study are globally similar to those reported in the literature, which can conclude on the contribution of Ropivacaïne compared to Bupivacaïne in terms of efficacy and tolerance, with early ambulation. Finally, it can be used as a possible alternative to Bupivacaïne in loco regional anesthesia.